Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
Status:
Enrolling by invitation
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the potential effectiveness of Cosentyx in
the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.